Navigation Links
Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Date:6/16/2010

2009 and reports on Form 10-Q for the quarter ended March 31, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

Abbott Forward Looking Statement

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and in Item 1A, "Risk Factors," to our Quarterly Report on Securities and Exchange Commission Form 10-Q for the period ended March 31, 2010, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
2. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramals Healthcare Solutions Business
3. Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
4. Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott Declares 343rd Consecutive Quarterly Dividend
7. Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
8. Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
9. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
10. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
11. Abbott HIV Test Demonstrates Earlier Disease Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... /CNW/ - MaRS and Virgin Unite Canada, the non-profit foundation ... forces to support Canadian entrepreneurs tackling social and environmental challenges. ... at the MaRS Centre to announce the new partnership, which ... This fund has $1 million in seed capital provided by ... Mindset Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... SeqWright Inc., a world-wide leader in custom genomic ... strides to position itself as the Next-Generation Sequencing ... can be attributed to the company,s ability to ... in key genomics technologies. Building on this success, ...
... 11, 2011 Regenicin, Inc. (OTC Bulletin Board: ... development of regenerative cell therapies to restore the health ... 4th annual OneMedForum at the Sir Francis Drake Hotel ... Randall McCoy, will present Regenicin,s core business model and ...
... 2011 AstraZeneca (NYSE: AZN ) and ... advancing therapies for cancer patients through clinical research, today ... a novel targeted oncology compound from AstraZeneca. ... accounting for 7.4 million (or 13%) of all deaths ...
Cached Biology Technology:SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 3
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... recent surge of DNA sequence information resulting from deciphering ... for innovative technological developments that have been vital in ... has allowed for the development of novel genetic therapies ... The new genomic era heralds earlier diagnoses, greatly ...
... fluorescence is an effective way of determining how ... technique described in the open access journal ... a quantitative and precise determination of viability in ... demands of industrial, municipal and agricultural consumption on ...
... widespread in the animal kingdom than previously thought. A ... fiddler crabs "lie" about their fighting ability by growing ... fact weak and puny. Published this week in the ... study is the first direct evidence that crabs "bluff" ...
Cached Biology News:Personalized medicine: Innovative online journal leads the way 2Fiddler crabs reveal honesty is not always the best policy 2Fiddler crabs reveal honesty is not always the best policy 3
... for western blots ,• Optically clear plastic ... staining western blots. The reduced size (60 ... disposable tray requires less dye and antibodies ... the user. Pour spouts in each corner ...
... pLivSelect is a ... for recombinant identification. Recombinant ... colony survival, eliminating the ... screening. This quick and ...
... Qentix Western Blot Signal Enhancer does for enzyme-/substrate-based ... it increases the signal up to 10-fold ... minutes., ,The Western Blot Signal Enhancer membrane ... be added to your current Western blotting ...
... Solid phase extraction through columns is ... range of applications. Typical applications are in ... in diagnostics, or compound purification in chemical ... fully automated on the Genesis series instruments ...
Biology Products: